Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus, and body composition in rat models

Endocrinology

Volumn 139, Issue 4, 1998, Pages 2068-2076

  Ke, Hua Zhu ^a   Paralkak, Vishwas M ^a   Grasser, William A ^a   Crawford, D Todd ^a   Qi, Hong ^a   Simmons, Hollis A ^a   Pirie, Christine M ^a   Chidsey Frink, Kristin L ^a   Owen, Thomas A ^a   Smock, Steven L ^a   Chen, Hong Ka ^b   Jee, Webster S S ^b   Cameron, Kimberly O ^a   Rosati, Robert L ^a   Brown, Thomas A ^a   Dasilva Jardine, Paul ^a   Thompson, David D ^a  

^a PFIZER INC   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(4' PYRROLIDINOETHOXYPHENYL)PHENYL 6 HYDROXY 1,2,3,4 TETRAHYDRONAPTHALENE DEXTRO TARTRATE; ACID PHOSPHATASE; ANTIESTROGEN; CHOLESTEROL; ESTRADIOL; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR; OSTEOCALCIN; PROTEIN P53; UNCLASSIFIED DRUG;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BODY MASS; BONE TURNOVER; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GENE EXPRESSION; MULTINUCLEAR CELL; NONHUMAN; ORAL DRUG ADMINISTRATION; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RAT; UTERUS WEIGHT; WEIGHT GAIN;

EID: 0001236520     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.139.4.5902     Document Type: Article

References (36)

1. Jordan VC, Phelps E, Lindgren JU 1987 Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 10:31-35
2. Lerner LJ, Jordan VC 1990 Development of antiestrogen and their use in breast cancer: Eighth Memorial Award Lecture. Cancer Res 50:4177-4189
3. Bryant HU, Glasebrook AL, Yang NN, Sato M 1996 A pharmacological review of raloxifene. J Bone Miner Metab 14:1-9
4. Thompson DD, Chen HK, Crawford DT, Qi H, Pine CM, Simmons HA, Grasser WA, Jee WSS, Ke HZ 1995 Beneficial effects of droloxifene, a new estrogen antagonist/agonist, in preclinical studies. In: Liu Z, Xue Y (eds) Advances in Osteoporosis. International Academic Publishers, Beijing, China, vol 2:606-613
5. Lobo A 1995 Benefits and risks of estrogen replacement therapy. Am J Obstet Gynecol 173:982-990
6. Whitehead MI, Fraser D 1987 Controversies concerning the safety of estrogen replacement therapy. Am J Obstet Gynecol 156:1313-1322
7. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE 1995 The use of estrogen and progestins and the risk of breast cancer in postmenopausal women. N Eng J Med 332:1589-1593
8. Evans GL, Turner RT 1995 Tissue-selective actions of estrogen analogs. Bone [Suppl] 17:181S-190S
9. Eppenberger U, Wosikowski K, Kung W 1991 Pharmacologic and biological properties of droloxifene, a new antiestrogen. Am J Clin Oncol [Suppl 2] 14:S5-S14
10. Wakeling AE, Valcaccia B, Newboult E, Green LR 1984 Nonsteroidal antiestrogens-receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells. J Steroid Biochem Mol Biol 20:111-120
11. Love RR, Bardon HS, Mazess RB, Epstein S, Chappell RJ 1994 Effects of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 154:2585-2588
12. Ward RL, Morgan G, Dalley D, Kelly PJ 1993 Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. Bone Miner 22:87-94
13. Turner RT, Wakley GK, Hannon KS, Bell NH 1988 Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone deficient rats. Endocrinology 122:1146-1150
14. Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO 1994 Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 343:1318-1321
15. Greaves P, Goonetilleke R, Numm G, Topham J, Orton T 1993 Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res [Suppl 1] 53:3919-3924
16. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Gullinan GJ, Bendele R, Kauffman RR, Bensch WR, Frolik CA, Termine JD, Bryant HU 1994 Raloxifene (LY 139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93:63-69
17. Turner CH, Sato M, Bryant HU 1994 Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology 135:2001-2005
18. Ke HZ, Simmons HA, Pirie CM, Crawford DT, Thompson DD 1995 Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. Endocrinology 136:2435-2441
19. Ke HZ, Chen HK, Qi H, Pirie CM, Simmons HA, Ma YF, Jee WSS, Thompson DD 1995 Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats. Bone 17:491-496
20. Chen HK, Ke HZ, Jee WSS, Ma YF, Pirie CM, Simmons HA, Thompson DD 1995 Droloxifene prevents ovariectomy-induced bone loss in tibiae and femora of aged female rats: a dual-energy x-ray absorptiometric and histomorphometric study. J Bone Miner Res 10:1256-1262
21. Ke HZ, Chen HK, Simmons HA, Qi H, Crawford DT, Pirie CM, Chidsey-Frink KL, Ma YF, Jee WSS, Thompson DD 1997 Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model. Bone 20:31-39
22. Frost HM, Jee WSS 1992 On the rat model of human osteopenias and osteoporosis. Bone Miner 18:227-236
23. Kalu DN 1991 The ovariectomized rat model of postmenopausal bone loss. Bone Miner 15:175-192
24. Wronski TJ, Yen CF 1991 The ovariectomized rat model as an animal model for postmenopausal bone loss. Cell Materials [Suppl 1], pp 69-74
25. Grasser WA, Pan LC, Thompson DD, Paralkar VM 1997 Common mechanism for the estrogen agonist and antagonist activities of droloxifene. J Cell Biochem 65:159-171
26. Obourn JD, Koszewski NJ, Notides AC 1993 Hormone- and DNA-binding mechanisms of the recombinant human estrogen receptor. Biochemistry 32:6229-6239
27. Frost HM 1969 Tetracycline-based histologic analysis of bone remodeling. Calcif Tissue Int 3:211-237
28. Price PA, Nishimoto SK 1980 Radioimmunoassay for the vitamin K-dependent protein of bone and its discovery in plasma. Proc Natl Acad Sci USA 77:2234-2238
29. Baron R, Vignery A, Neff L, Silverglate A, Maria AS 1983 Processing of undecalcified bone specimens for bone histomorphometry. In: Recker RR (ed) Bone Histomorphometry: Techniques and Interpretation. CRC Press, Boca Raton, FL, pp 13-36
30. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Miner Res 2:595-610
31. Jee WSS, Inoue J, Jee KW, Haba T 1983 Histomorphometric assay of the growing long bone. In: Takahashi H (ed) Handbook of Bone Morphology. Nishimusa, Niigata City, Japan, pp 101-122
32. Neter J, Wasserman W, Ahitmore GA 1982 Applied Statistics. Allyn and Bacon, Boston, pp 544-572
33. Cauley JA, Deeley DG, Ensrud K, Ettinger B, Black D, Cummings SR 1995 Estrogen replacement therapy and fractures in older women. Ann Intern Med 122:9-16
34. Maxim P, Ettinger B, Spitalny GM 1995 Fracture protection provided by long-term estrogen treatment. Osteoporos Int 5:23-29
35. Beresford SA, Weiss NS, Voigt LF, Mcknight B 1997 Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestogen therapy in postmenopausal women. Lancet 349:458-461
36. Chao Y, Windler EE, Chen GC, Havel RJ 1979 Hepatic catabolism of rat and human lipoproteins in rats treated with 17α-ethynyl estradiol. J Biol Chem 254:11360-11366